Search
SC-236
go.drugbank.com/drugs/DB14059ExperimentalSC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and inflammation [A33373], [A33374
VX-702
go.drugbank.com/drugs/DB05470InvestigationalIt acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
Sodium chlorite
go.drugbank.com/drugs/DB13210InvestigationalUsed as an agent for cleaning drinking water. It is also used as an additive in products like toothpaste and mouthwash. Acidified sodium chlorite was approved by the U.S. … Food and Drug Administration as of 2004, as an anti-microbial agent which is non-toxic, but not as a drug [A174811, L5413].
Fasedienol
go.drugbank.com/drugs/DB04968InvestigationalIt is a member of a new family of pharmaceutical compounds called vomeropherins.
CRx-139
go.drugbank.com/drugs/DB05744ExperimentalIt is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously.
Gantacurium
go.drugbank.com/drugs/DB05710InvestigationalIt is being developed by Avera Pharmaceuticals.
Elzovantinib
go.drugbank.com/drugs/DB18918InvestigationalElzovantinib is under investigation in clinical trial NCT03993873 (Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET).
Toyocamycin
go.drugbank.com/drugs/DB13916ExperimentalIt is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.
MF-300
go.drugbank.com/drugs/DB32060InvestigationalMF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase. … As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236